Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Vigabatrin (generic Sabril)

Notes:

- ^ Adequate trial is defined as 1-month treatment duration
- + Antiepileptic medication for treatment of partial (focal) onset seizures include: carbamazepine, felbamate, gabapentin, lamotrigine, levetiracetam, phenytoin, pregabalin, tiagabine, topiramate, oxcarbazepine, valproate, and zonisamide

<u>Initiation (new start) criteria</u>: Non-formulary **vigabatrin (generic Sabril)** will be covered on the prescription drug benefit for <u>3 months</u> when the following criteria are met:

- Prescribed for the treatment of refractory, partial (focal) seizures AND
 - Prescribed by a Neurologist
 - Patient has failed an adequate trial[^] of, or patient has an allergy or intolerance^{*} to at least 3 other antiepileptic medications (AEDs) indicated for partial (focal) onset seizures⁺
 - Patient has completed mandatory ophthalmic evaluation within 4 weeks of treatment initiation

-OR-

- Prescribed for the treatment of infantile spasms AND
 - Prescribed by a Neurologist

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary vigabatrin (generic Sabril) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed for the treatment of refractory, partial (focal) seizures OR infantile spasms
- Prescribed by a Neurologist
- Ophthalmic evaluation has been completed within the past 3 months
- Patient has been assessed by neurologist within past 12 months

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>. Non-formulary vigabatrin
(generic Sabril) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

kp.org

Revised: 10/10/19 Effective: 11/21/19 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Vigabatrin (generic Sabril)

- Prescribed for seizures or infantile spasms
- Ophthalmic evaluation has been completed within the past 3 months
- If prescribed for seizures, patient failed an adequate trial[^] of, or patient has an allergy or intolerance^{*} to at least 3 other antiepileptic medications (AEDs) indicated for partial (focal) onset seizures⁺

<u>Continued use criteria (3 months after initiation):</u> Non-formulary **vigabatrin (generic Sabril)** will continue to be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Prescribed by a neurologist
- Patient has been assessed by neurologist since initiation and has realized benefit from treatment, per neurologist documentation

<u>Continued use criteria for patients stable on the medication:</u> Non-formulary <u>vigabatrin (Sabril)</u> will continue to be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Prescribed by a neurologist
- Ophthalmic evaluation has been completed within the past 3 months
- Patient has been assessed by neurologist within past 12 months

kp.org

Revised: 10/10/19 Effective: 11/21/19 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

